Scientists have identified a human virus comparable to COVID-19.

The human respiratory syncytial virus (RSV) may be comparable in severity to influenza and coronavirus. This is the conclusion reached by Singaporean researchers collaborating as part of the PREPARE program, according to the press service of the Singapore General Hospital.

Scientists conducted three studies to assess the severity of the disease, the risk of cardiac complications, and its long-term consequences. As one of the study's authors, Ian Wee, noted, RSV infection occurs in 5 to 10% of patients experiencing flu-like symptoms. He emphasized that this does not make the disease "less serious" than influenza and coronavirus .

After analyzing approximately 13,000 cases of adult hospitalization due to RSV,Between COVID-19 and influenza, scientists concluded that RSV kills one in 20 (5%) patients. Therefore, the mortality rate from RSV is higher than that of influenza, and the severity of the disease is comparable to COVID-19.

Furthermore, one in ten (10%) of those hospitalized with RSV were diagnosed with cardiovascular problems. The risk of cardiac complications from RSV was higher than from coronavirus.

Respiratory syncytial virus (RSV) was first discovered in 1956 by American researchers while studying an outbreak of respiratory disease in laboratory chimpanzees . In 1957, RSV was also isolated in humans—in children with acute respiratory infections, after which the virus received its current name.

Finally, the scientists found that adult patients who had RSV had a persistent increased risk of developing long-term cardiovascular and neurological complications for 300 days after hospitalization. Children, on the other hand, had a higher risk of respiratory complications than those with influenza or coronavirus.

ReadPIONERPRODUKT .by inTELEGRAM .